Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia

J Thorac Oncol. 2024 Apr;19(4):547-550. doi: 10.1016/j.jtho.2024.01.017.

Authors

Illaa Smesseim¹, Paul Baas²

Affiliations

¹ Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands and Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
² Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands and Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: [email protected].

PMID: 38582547
DOI: 10.1016/j.jtho.2024.01.017

No abstract available

Publication types

Editorial

MeSH terms

Humans
Immunotherapy / methods
Lung Neoplasms* / pathology
Lung Neoplasms* / therapy
Mesothelioma* / pathology
Mesothelioma* / therapy
Mesothelioma, Malignant*
Pleural Neoplasms* / pathology
Pleural Neoplasms* / therapy